Hemorragia encefálica por angiopatía amiloidea

Amyloid angiopathy (AA) is a selective deposition of amyloid in the walls of the brain vessels. It is a form of sporadic and localized amyloidosis, constituted by the Aβ4 protein, the same of Alzheimer's disease senile plaques. The most consistent clinical effect of AA is spontaneous b...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Tapia,Jorge
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2021
Materias:	Cerebral Amyloid Angiopathy Cerebral Hemorrhage Stroke Cerebral Small Vessel Diseases
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100076
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872021000100076
record_format	dspace
spelling	oai:scielo:S0034-988720210001000762021-05-09Hemorragia encefálica por angiopatía amiloideaTapia,Jorge Cerebral Amyloid Angiopathy Cerebral Hemorrhage Stroke Cerebral Small Vessel Diseases Amyloid angiopathy (AA) is a selective deposition of amyloid in the walls of the brain vessels. It is a form of sporadic and localized amyloidosis, constituted by the Aβ4 protein, the same of Alzheimer's disease senile plaques. The most consistent clinical effect of AA is spontaneous brain hemorrhage (BH). It is the second most common cause of BH after arterial hypertension (HT). Other clinical manifestations are cognitive impairment and transient focal neurological episodes. AA BH is characteristically localized in the cerebral cortex and subcortical white matter (lobar hemorrhage), consistent with the preferential deposit of amyloid in the walls of leptomeningeal and intracortical small cerebral vessels. Other types of AA hemorrhagic complications are microbleeds (MB), cerebral convexity subarachnoid hemorrhage (cSAH) and superficial hemosiderosis (cSS). The diagnosis of AA BH is based on the Boston criteria. Using these criteria, several non-hemorrhagic biomarkers of AA have been identified that can be useful in its diagnosis. The principal AA BH risk factor is age, followed by cSS, MB, Apolipoprotein E gen ε2 and ε4 alleles, HT and the use of antithrombotics. This condition has a high recurrence rate that shares the same risk factors. There is no specific treatment for AA BH. It has a better prognosis than HT BH during the acute period, but worse on the long term, due to its high recurrence rate and cognitive impairment.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.149 n.1 20212021-01-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100076es10.4067/S0034-98872021000100076
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Cerebral Amyloid Angiopathy Cerebral Hemorrhage Stroke Cerebral Small Vessel Diseases
spellingShingle	Cerebral Amyloid Angiopathy Cerebral Hemorrhage Stroke Cerebral Small Vessel Diseases Tapia,Jorge Hemorragia encefálica por angiopatía amiloidea
description	Amyloid angiopathy (AA) is a selective deposition of amyloid in the walls of the brain vessels. It is a form of sporadic and localized amyloidosis, constituted by the Aβ4 protein, the same of Alzheimer's disease senile plaques. The most consistent clinical effect of AA is spontaneous brain hemorrhage (BH). It is the second most common cause of BH after arterial hypertension (HT). Other clinical manifestations are cognitive impairment and transient focal neurological episodes. AA BH is characteristically localized in the cerebral cortex and subcortical white matter (lobar hemorrhage), consistent with the preferential deposit of amyloid in the walls of leptomeningeal and intracortical small cerebral vessels. Other types of AA hemorrhagic complications are microbleeds (MB), cerebral convexity subarachnoid hemorrhage (cSAH) and superficial hemosiderosis (cSS). The diagnosis of AA BH is based on the Boston criteria. Using these criteria, several non-hemorrhagic biomarkers of AA have been identified that can be useful in its diagnosis. The principal AA BH risk factor is age, followed by cSS, MB, Apolipoprotein E gen ε2 and ε4 alleles, HT and the use of antithrombotics. This condition has a high recurrence rate that shares the same risk factors. There is no specific treatment for AA BH. It has a better prognosis than HT BH during the acute period, but worse on the long term, due to its high recurrence rate and cognitive impairment.
author	Tapia,Jorge
author_facet	Tapia,Jorge
author_sort	Tapia,Jorge
title	Hemorragia encefálica por angiopatía amiloidea
title_short	Hemorragia encefálica por angiopatía amiloidea
title_full	Hemorragia encefálica por angiopatía amiloidea
title_fullStr	Hemorragia encefálica por angiopatía amiloidea
title_full_unstemmed	Hemorragia encefálica por angiopatía amiloidea
title_sort	hemorragia encefálica por angiopatía amiloidea
publisher	Sociedad Médica de Santiago
publishDate	2021
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872021000100076
work_keys_str_mv	AT tapiajorge hemorragiaencefalicaporangiopatiaamiloidea
_version_	1718437178335297536

Hemorragia encefálica por angiopatía amiloidea

Ejemplares similares